Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.
about
Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1Low-cost, high-throughput, automated counting of bacterial coloniesA second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cellsA Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein AntigensIssues and challenges in the development of pneumococcal protein vaccinesCrystal structures of respiratory pathogen neuraminidasesEpidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factorsAre the currently existing anti-human papillomavirus vaccines appropriate for the developing world?Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacementA current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United StaPneumococcal Disease in the Era of Pneumococcal Conjugate VaccinePneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg APneumococcal capsular polysaccharide structure predicts serotype prevalenceThe prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, KenyaMaternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspringMultiple colonization with S. pneumoniae before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccinePopulation structure of invasive Streptococcus pneumoniae isolates among Alaskan children in the conjugate vaccine era, 2001 to 2013.Streptococcus pneumoniae non-susceptibility and outpatient antimicrobial prescribing rates at the Alaska Native Medical CenterEffect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--Alaska, 2008-2012.Molecular epidemiology of serotype 19A Streptococcus pneumoniae among invasive isolates from Alaska, 1986-2010International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005Role of conjugative elements in the evolution of the multidrug-resistant pandemic clone Streptococcus pneumoniaeSpain23F ST81Parapneumonic empyema deaths during past century, Utah.Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah.Contribution of vaccines to our understanding of pneumococcal disease.Molecular characterization of Streptococcus pneumoniae serotype 12F isolates associated with rural community outbreaks in AlaskaUsing pneumococcal carriage data to monitor postvaccination changes in invasive disease.Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland.Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure dataVaccine escape recombinants emerge after pneumococcal vaccination in the United States.Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodiesImpact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population.Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination.Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccineEmerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001.Self-reported pediatricians' management of the well-appearing young child with fever without a source: first survey in an European country in the anti-pneumococcal vaccine era.Genetic diversity of the pneumococcal capsule: implications for molecular-based serotyping.Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adultsDynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.
P2860
Q24600699-88AC4153-D196-468B-85DC-64BB89D6CCA2Q24603906-07BEC6BE-45B0-486B-8BDF-32C16400CDFAQ24651147-C42D5CF9-0EAE-46E0-BEBD-02EADC0AEC3BQ26753152-60EC2EE5-A649-4562-8B79-670476663969Q26823701-6D3A80BE-EAEA-402C-AB6E-5111D3515D89Q27654091-343FDB28-9367-4AF0-BC06-C9BA06BA351DQ27685556-C425C120-D9E0-4090-9A75-B21FFD0E486EQ27692056-BB9894A7-4D1F-4FD5-9150-633D71D218B3Q28069508-F6404762-3053-4AF7-9509-AA88E92CBF0FQ28085452-C27DC286-64CD-4592-984D-8E27A08D2398Q28088610-A32AA64F-E5BD-4654-8398-9F56A549EA3EQ28472283-719E1CA4-7B01-44ED-B608-E659D398CE69Q28475595-5A194406-9847-44DA-B75E-B70115DB1C8AQ28731923-F4737FCA-443A-44D9-A63F-28F6B7D0E650Q28743311-0F3A7415-6B97-45E4-9ECC-41B8F6F73A0DQ28750319-C5BEE6BB-5344-4413-8FED-19EDB250BCBEQ30151859-67236F35-8AA8-46EB-9A47-792117450FBBQ30218061-6106C756-0ED4-4376-92C5-715103FD45A7Q30218803-C1EF7030-0141-46A1-A628-C0F24C3BC648Q30220968-99DE9233-C4E3-4BFB-9384-22A58EA69473Q30229113-391107A3-0006-4959-B530-70328DF61BCEQ30374128-F07A73B7-8E3C-4C31-A61A-BB003A952124Q30374152-CA907644-5163-4C68-B308-CDAA6000D4EEQ30388317-E3573155-1236-4B63-8488-C34275FE85B4Q30406750-CD09ECF9-B7D8-4833-BF74-303D85DE4A41Q30539635-CD4D2BDB-04E3-4407-9C7B-42218065807FQ30665494-D55B58D4-48C2-4420-BF51-D84022B3F952Q31125433-AD675CAD-93A5-4944-B3AB-EF4CB4F7DBECQ31158788-DD4990A1-DB96-40C9-B065-74E6803B8F1DQ33306103-BEFEFE21-0737-44C5-B036-491E04888A42Q33312893-4997BEBA-4D18-4DE7-A34A-9FE06E64942EQ33370549-D5E5D559-FE91-4EF5-8842-006C1395814FQ33410695-4BF0C7F2-F0F2-4FCB-98E5-AF4F6BF7329AQ33470299-550F51CB-C44F-40E7-A6E8-4D51A5A0B178Q33489894-CBF961C1-12C0-4128-AB23-15E7A26E84CDQ33494765-5825B665-AACC-40B5-BD64-7D27D0E40728Q33499040-E7401359-0A07-4262-8829-DA587811D5E7Q33528283-734F4519-2847-42AF-9A16-6ADD30E7DEFDQ33530554-F5944511-C89F-466C-B7B3-1B4B081AE588Q33551026-001FBD6A-8FB8-4E0B-A752-A645436A427D
P2860
Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@ast
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@en
type
label
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@ast
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@en
prefLabel
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@ast
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@en
P2093
P356
P1476
Invasive pneumococcal disease ...... al conjugate vaccine coverage.
@en
P2093
Alan Parkinson
Debby A Hurlburt
Jay C Butler
Karen Rudolph
Laura L Hammitt
Lisa R Bulkow
Rosalyn J Singleton
Tammy Zulz
P304
P356
10.1001/JAMA.297.16.1784
P407
P577
2007-04-01T00:00:00Z